摘要
目的观察选择性β1受体阻滞剂琥珀酸美托洛尔缓释片（Betaloc ZOK,简称倍他洛克缓释片）治疗轻中度原发性高血压的疗效和安全性。方法30例轻中度原发性高血压患者服用倍他洛克缓释片47.5～95 mg/d 8周。治疗前后测量坐位血压,监测肝肾功能、血糖、血脂,记录药物不良反应。结果治疗8周后,收缩压和舒张压分别下降（13.70±17.70）mm Hg和（11.03±9.85）mm Hg（P均〈0.001）,26/30例患者血压〈140/90 mm Hg,降压达标率为86.7%。心率、肝功能和血糖、血脂指标治疗前后差异无统计学意义。血肌酐显著下降[（0.92±0.2）mg/dlvs.（0.79±0.20）mg/dl,P〈0.001]。结论倍他洛克缓释片能有效治疗轻中度原发性高血压,无明显不良反应,患者依从性良好。
Objective To observe the efficacy and safety of extended-release metoprolol succinate（Betaloc ZOK,a new-style repository preparation of selective beta1-adrenergic blocker） in treatment of patients with mild to moderate primary hypertension.Methods Thirty patients of mild to moderate primary hypertension were given 47.5-95 mg/d Betaloc ZOK for 8 weeks.Blood pressure,renal function,hepatic function,blood glucose and lipid were measured,and adverse events were recorded before and after treatment.Results After treatment,systolic and diastolic blood pressure were decreased by（13.70±17.7）mm Hg and（11.03±9.85）mm Hg respectively（P〈0.001）.There were 86.7% patients with blood pressure less than 140/90 mm Hg.Heart rate,hepatic function,blood glucose and lipid did not change significantly before and after treatment.However,serum creatinine level reduced significantly after treatment compared with before（0.79±0.20mg/dl vs.0.92±0.2 mg/dl,P〈0.001）.Conclusions Betaloc ZOK can effectively treat the patients of mild to moderate primary hypertension with good compliance and no obvious adverse events.
出处
《中国心血管杂志》
2007年第4期287-289,共3页
Chinese Journal of Cardiovascular Medicine
关键词
美托洛尔缓释片
原发性高血压
Extended-release metoprolol succinate
Primary hypertension
